RNAi therapeutic intervention of human viral respiratory disease

RNAi对人类病毒性呼吸道疾病的治疗干预

• 批准号: nhmrc : 508601
• 负责人: A/Pr Kirsten Spann
• 金额: $ 38.95万
• 依托单位: Griffith University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/rnai-therapeutic-intervention-respiratory-disease/99449
• 关键词: RNAi; therapeutic; intervention; human; viral

Human metapneumovirus (HMPV), causes clinical disease that is very similar to human respiratory syncytial virus (RSV) and co-circulates with RSV. HMPV is emerging as a major cause of morbidity and life-threatening respiratory tract disease in infants, young children and the elderly worldwide. No treatment is currently available. The objectives of this proposal are to develop novel antiviral drugs that silence the expression of viral genes and to examine protection against the disease.

人类偏肺病毒 (HMPV) 引起的临床疾病与人类呼吸道合胞病毒 (RSV) 非常相似，并与 RSV 共同循环。 HMPV 正在成为全世界婴儿、幼儿和老年人发病和危及生命的呼吸道疾病的主要原因。目前没有可用的治疗方法。该提案的目的是开发新型抗病毒药物，沉默病毒基因的表达并检查对这种疾病的保护作用。